Answer
Yes, cytokine release syndrome, including fatal or life-threatening reactions, has occurred following Abecma (idecabtagene vicleucel) infusion.
Sources for this answer
- Abecma 260 - 500 x 10^6 cells dispersion for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 3Document updated
Sources checked